Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.

<h4>Introduction</h4>CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katsuhiro Yoshikawa, Mitsuaki Ishida, Hirotsugu Yanai, Koji Tsuta, Mitsugu Sekimoto, Tomoharu Sugie
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e1b61ea326794a06b2b5eb3adb0bcee7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1b61ea326794a06b2b5eb3adb0bcee7
record_format	dspace
spelling	oai:doaj.org-article:e1b61ea326794a06b2b5eb3adb0bcee72021-12-02T20:10:45ZImmunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.1932-620310.1371/journal.pone.0253176https://doaj.org/article/e1b61ea326794a06b2b5eb3adb0bcee72021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0253176https://doaj.org/toc/1932-6203<h4>Introduction</h4>CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail.<h4>Methods</h4>Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73-10 assays), was also examined.<h4>Results</h4>CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73-10 assay did not show a correlation (p = 0.115). Using the 73-10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively).<h4>Conclusions</h4>CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy.Katsuhiro YoshikawaMitsuaki IshidaHirotsugu YanaiKoji TsutaMitsugu SekimotoTomoharu SugiePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0253176 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Katsuhiro Yoshikawa Mitsuaki Ishida Hirotsugu Yanai Koji Tsuta Mitsugu Sekimoto Tomoharu Sugie Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
description	<h4>Introduction</h4>CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail.<h4>Methods</h4>Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73-10 assays), was also examined.<h4>Results</h4>CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73-10 assay did not show a correlation (p = 0.115). Using the 73-10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively).<h4>Conclusions</h4>CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy.
format	article
author	Katsuhiro Yoshikawa Mitsuaki Ishida Hirotsugu Yanai Koji Tsuta Mitsugu Sekimoto Tomoharu Sugie
author_facet	Katsuhiro Yoshikawa Mitsuaki Ishida Hirotsugu Yanai Koji Tsuta Mitsugu Sekimoto Tomoharu Sugie
author_sort	Katsuhiro Yoshikawa
title	Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
title_short	Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
title_full	Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
title_fullStr	Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
title_full_unstemmed	Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
title_sort	immunohistochemical analysis of cd155 expression in triple-negative breast cancer patients.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/e1b61ea326794a06b2b5eb3adb0bcee7
work_keys_str_mv	AT katsuhiroyoshikawa immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT mitsuakiishida immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT hirotsuguyanai immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT kojitsuta immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT mitsugusekimoto immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT tomoharusugie immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients
_version_	1718374976633962496

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.

Ejemplares similares